Compare THH & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | QNCX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Japan | United States |
| Employees | 116 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 19.9M |
| IPO Year | N/A | 2019 |
| Metric | THH | QNCX |
|---|---|---|
| Price | $0.38 | $1.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.0K | ★ 1.5M |
| Earning Date | 05-19-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $305.05 | ★ $0.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.08 |
| 52 Week High | $56.26 | $4.55 |
| Indicator | THH | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 49.56 |
| Support Level | $0.31 | $0.10 |
| Resistance Level | $0.54 | $1.50 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 80.14 | 50.89 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.